Artelo Biosciences (ARTL) Registration filing summary

Company overview and business model

• Clinical-stage biopharmaceutical company focused on developing therapeutics targeting lipid-signaling modulation pathways, including the endocannabinoid system.

• Pipeline includes ART27.13 (dual cannabinoid agonist for cancer-related anorexia), ART26.12 (FABP5 inhibitor for chemotherapy-induced peripheral neuropathy and other indications), and ART12.11 (CBD cocrystal for multiple potential indications).

• Product candidates are developed in accordance with regulated drug development standards, aiming for prescription-based commercialization post-approval.

• Holds multiple patents and licenses, including exclusive rights to ART27.13 and a library of FABP5 inhibitors.

Financial performance and metrics

• As of December 31, 2025, cash and cash equivalents were $600,000; pro forma as-adjusted cash post-offering estimated at $11.5 million.

• Accumulated deficit of $63.0 million and stockholders' equity of $(1.3) million, projected to increase to $9.6 million post-offering.

• Net tangible book value per share as of December 31, 2025, was $(4.92); expected to increase to $4.16 per share after the offering.

Use of proceeds and capital allocation

• Estimated net proceeds of $10.9 million (assuming all securities sold) to be used for working capital and general corporate purposes.

• Management retains broad discretion over the application of proceeds.